· The latest circVec 3.0 generation of its circular RNA therapeutic platform
technology has now been validated in multiple vector formats
  · New delivery data demonstrates efficient delivery to the spleen, opening
novel circVec opportunities in cell therapy
  · Rich pipeline of upcoming R&D milestones, including several existing and new
research collaborations
  · Presentation of 2024 financial results, including ongoing activities to
strengthen CircioŽs financial position

Oslo, Norway 26 March 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing powerful circular RNA technology for next generation nucleic
acid medicine, is hosting a live webcast at 10:00am CET today Wednesday 26 March
2025. In the webcast, Circio management will present the 2024 financial results,
provide a general corporate update and present the latest developments for the
circVec platform technology.

The presentation will show the advantages and potential of Circio's newest
circVec 3.0 generation and ongoing activities to validate its performance in
therapeutic vector formats. In addition, recent systemic LNP-delivery data will
be discussed that demonstrate robust and durable circVec expression in the
spleen, far outperforming equivalent mRNA-vectors. This important finding
creates potential therapeutic opportunities for the circVec technology in new
areas, such as cell therapy.

"Circio's latest results showing efficient and specific LNP-delivery to the
spleen are very promising and have the potential to open up novel opportunities
for the circVec platform in cell and immune therapies," said Dr. Erik D Wiklund,
CEO of Circio. "We now have a broad set of ongoing experiments, both internally
and through several external research collaborations, that are generating
multiple important in vivo data read outs during Q2. The performance of circVec
3.0-AAV constructs is of particular importance, with the potential to generate
substantial near-term partnering interest."

A summary of the financial results for 2024 and corporate outlook for 2025 will
also be covered in the presentation. During 2024, Circio completed both a rights
issue and private placement, strengthening the financial situation and
shareholder base of the company. In parallel, substantial cost saving measures
were implemented, thereby extending the cash runway and enabling maximized R&D
progress on a low cost base. A multi-pronged strategy is being pursued to secure
long-term funding, including extension of the Atlas financing commitment,
fundraising and structural and business development transactions.

Presenters:
CEO Dr. Erik Digman Wiklund
CFO Dr. Lubor Gaal

Time: 10:00 CET on 26 March 2025

click here to access the Teams webcast (https://teams.microsoft.com/l/meetup
-join/19%3ameeting_ZmVlODI4ZTktZDFmMC00MjliLWFmNDItMDA5NTJkZjdlMGQ1%40thread.v2/
0
?context=%7b%22Tid%22%3a%2266b0661a-3ec3-48a8-a966
-5b0cce82b3fe%22%2c%22Oid%22%3a%223f5f84b0-5521-4c04-bd8a-e185546abe04%22%7d)
Meeting ID: 392 868 593 190
Passcode: Mn7uS2qQ

Participate by phone:
+47 21402155
Phone conference ID: 394 288 903#

A recording of the webcast will be made available on the Circio
webpage (http://www.circio.com/)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: [email protected]

Lubor Gaal, CFO
Phone: +34 683343811
Email: [email protected]

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform technology
for nucleic acid and viral therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 of the Norwegian Securities Trading
Act.

This stock exchange announcement was published by Erik Digman Wiklund, CEO, on
behalf of the Company, at the time and date stated above in this announcement.